Cargando…

Trends in Radiation Oncology Treatment Fractionation at a Single Academic Center, 2010 to 2020

PURPOSE: Recent clinical trials suggest hypofractionated treatment regimens are appropriate for treatment of many cancers. It is important to understand and document hypofractionation adoption because of its implications for treatment center patient volumes. There is no recent U.S. study of trends i...

Descripción completa

Detalles Bibliográficos
Autores principales: Cher, Benjamin A.Y., Dykstra, Michael, Wang, Chang, Schipper, Matthew, Hayman, James A., Mayo, Charles S., Jagsi, Reshma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441303/
https://www.ncbi.nlm.nih.gov/pubmed/36072755
http://dx.doi.org/10.1016/j.adro.2022.101032
_version_ 1784782540700123136
author Cher, Benjamin A.Y.
Dykstra, Michael
Wang, Chang
Schipper, Matthew
Hayman, James A.
Mayo, Charles S.
Jagsi, Reshma
author_facet Cher, Benjamin A.Y.
Dykstra, Michael
Wang, Chang
Schipper, Matthew
Hayman, James A.
Mayo, Charles S.
Jagsi, Reshma
author_sort Cher, Benjamin A.Y.
collection PubMed
description PURPOSE: Recent clinical trials suggest hypofractionated treatment regimens are appropriate for treatment of many cancers. It is important to understand and document hypofractionation adoption because of its implications for treatment center patient volumes. There is no recent U.S. study of trends in hypofractionation adoption that includes comparisons of multiple disease sites and data since the onset of COVID-19. In this context, this study describes trends in treatment fractionation at a single academic center from 2010 to 2020. METHODS AND MATERIALS: From an institutional database, records were extracted for treatment of 4 disease site categories: all cancers, breast cancer, prostate cancer, and bone metastases. For each disease site, the mean number of fractions per treatment course was reported for each year of the study period. To explore whether the COVID-19 pandemic was associated with increased hypofractionation adoption, piecewise linear regression models were used to estimate a changepoint in the time trend of mean monthly number of fractions per treatment course and to evaluate whether this changepoint coincided with pandemic onset. RESULTS: The data set included 22,865 courses of radiation treatment and 375,446 treatment fractions. The mean number of fractions per treatment course for all cancers declined from 17.5 in 2010 to 13.6 in 2020. There was increased adoption of hypofractionation at this institution for all cancers and specifically for both breast and prostate cancer. For bone metastases, hypofractionation had largely been adopted before the study period. For most disease sites, adoption of hypofractionated treatment courses occurred before pandemic onset. Bone metastases was the only disease site where a pandemic-driven increase in hypofractionation adoption could not be ruled out. CONCLUSIONS: This study reveals increasing use of hypofractionated regimens for a variety of cancers throughout the study period, which largely occurred before the onset of the COVID-19 pandemic at this institution.
format Online
Article
Text
id pubmed-9441303
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94413032022-09-06 Trends in Radiation Oncology Treatment Fractionation at a Single Academic Center, 2010 to 2020 Cher, Benjamin A.Y. Dykstra, Michael Wang, Chang Schipper, Matthew Hayman, James A. Mayo, Charles S. Jagsi, Reshma Adv Radiat Oncol Scientific Article PURPOSE: Recent clinical trials suggest hypofractionated treatment regimens are appropriate for treatment of many cancers. It is important to understand and document hypofractionation adoption because of its implications for treatment center patient volumes. There is no recent U.S. study of trends in hypofractionation adoption that includes comparisons of multiple disease sites and data since the onset of COVID-19. In this context, this study describes trends in treatment fractionation at a single academic center from 2010 to 2020. METHODS AND MATERIALS: From an institutional database, records were extracted for treatment of 4 disease site categories: all cancers, breast cancer, prostate cancer, and bone metastases. For each disease site, the mean number of fractions per treatment course was reported for each year of the study period. To explore whether the COVID-19 pandemic was associated with increased hypofractionation adoption, piecewise linear regression models were used to estimate a changepoint in the time trend of mean monthly number of fractions per treatment course and to evaluate whether this changepoint coincided with pandemic onset. RESULTS: The data set included 22,865 courses of radiation treatment and 375,446 treatment fractions. The mean number of fractions per treatment course for all cancers declined from 17.5 in 2010 to 13.6 in 2020. There was increased adoption of hypofractionation at this institution for all cancers and specifically for both breast and prostate cancer. For bone metastases, hypofractionation had largely been adopted before the study period. For most disease sites, adoption of hypofractionated treatment courses occurred before pandemic onset. Bone metastases was the only disease site where a pandemic-driven increase in hypofractionation adoption could not be ruled out. CONCLUSIONS: This study reveals increasing use of hypofractionated regimens for a variety of cancers throughout the study period, which largely occurred before the onset of the COVID-19 pandemic at this institution. Elsevier 2022-07-22 /pmc/articles/PMC9441303/ /pubmed/36072755 http://dx.doi.org/10.1016/j.adro.2022.101032 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Scientific Article
Cher, Benjamin A.Y.
Dykstra, Michael
Wang, Chang
Schipper, Matthew
Hayman, James A.
Mayo, Charles S.
Jagsi, Reshma
Trends in Radiation Oncology Treatment Fractionation at a Single Academic Center, 2010 to 2020
title Trends in Radiation Oncology Treatment Fractionation at a Single Academic Center, 2010 to 2020
title_full Trends in Radiation Oncology Treatment Fractionation at a Single Academic Center, 2010 to 2020
title_fullStr Trends in Radiation Oncology Treatment Fractionation at a Single Academic Center, 2010 to 2020
title_full_unstemmed Trends in Radiation Oncology Treatment Fractionation at a Single Academic Center, 2010 to 2020
title_short Trends in Radiation Oncology Treatment Fractionation at a Single Academic Center, 2010 to 2020
title_sort trends in radiation oncology treatment fractionation at a single academic center, 2010 to 2020
topic Scientific Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441303/
https://www.ncbi.nlm.nih.gov/pubmed/36072755
http://dx.doi.org/10.1016/j.adro.2022.101032
work_keys_str_mv AT cherbenjaminay trendsinradiationoncologytreatmentfractionationatasingleacademiccenter2010to2020
AT dykstramichael trendsinradiationoncologytreatmentfractionationatasingleacademiccenter2010to2020
AT wangchang trendsinradiationoncologytreatmentfractionationatasingleacademiccenter2010to2020
AT schippermatthew trendsinradiationoncologytreatmentfractionationatasingleacademiccenter2010to2020
AT haymanjamesa trendsinradiationoncologytreatmentfractionationatasingleacademiccenter2010to2020
AT mayocharless trendsinradiationoncologytreatmentfractionationatasingleacademiccenter2010to2020
AT jagsireshma trendsinradiationoncologytreatmentfractionationatasingleacademiccenter2010to2020